Abstract
Background: Patients with psoriasis are at increased risk of NAFLD, and inflammation plays a role in both. As well, fatty liver grade correlates with C-reactive protein (CRP) levels. The anti–interleukin-17 receptor A antibody brodalumab is indicated for moderate/severe plaque psoriasis in adults who failed/lost response to other systemic therapies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
